CAM
GBT

Congress Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Congress Asset Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-26,224
Closed -$997K – 380
2018
Q3 		$997K Sell
26,224
-11,163
-30% -$494K 0.01% 304
2018
Q2 		$1.69M Hold
37,387
– – 0.02% 279
2018
Q1 		$1.81M Buy
37,387
+259
+0.7% +$14.4K 0.03% 279
2017
Q4 		$1.46M Sell
37,128
-17,445
-32% -$652K 0.02% 286
2017
Q3 		$1.69M Buy
+54,573
New +$1.53M 0.03% 271

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Congress Asset Management's GBT Position: Q4 2018 in Review

Congress Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2018, closing a stake of 26,224 shares — an estimated $997K sold.

Congress Asset Management first reported a position in GBT in Q3 2017 and held it in 5 quarters. The position peaked at $1.81M in Q1 2018. 190 funds tracked by Wall St. Rank hold GBT as of Q4 2018.

  • Congress Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2018 after selling out during the quarter.
  • Congress Asset Management sold 26,224 Global Blood Therapeutics, Inc. shares in Q4 2018, an estimated $997K.
  • Congress Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2017 and held it in 5 quarters.
  • Congress Asset Management's Global Blood Therapeutics, Inc. position peaked at $1.81M in Q1 2018.
  • 190 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2018.

Based on Congress Asset Management's 13F filing for Q4 2018, filed 25 Jan 2019.